A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact.
Clicks: 189
ID: 69173
2016
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
79.0
/100
188 views
152 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
In a Perspective accompanying Hill and colleagues, Elliot Marseille and James Kahn compare the history of pricing and availability of ART for HIV with that of the new HCV drugs and discuss strategies for providing treatment in LMIC even in the face of high costs.
| Reference Key |
marseille2016aplos
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Marseille, Elliot;Kahn, James G; |
| Journal | plos medicine |
| Year | 2016 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.